{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:33:20Z","timestamp":1785274400988,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.semarthrit.2014.01.004","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T04:00:13Z","timestamp":1390449613000},"page":"25-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Up-titration of allopurinol in patients with gout"],"prefix":"10.1016","volume":"44","author":[{"given":"Claudine G.","family":"Jennings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isla S.","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Nuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"Riches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Ralston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2014.01.004_bib1","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/ard.2007.076232","article-title":"Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000\u20132005","volume":"67","author":"Annemans","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ncprheum0556","article-title":"The changing epidemiology of gout","volume":"3","author":"Roddy","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib3","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1136\/ard.2008.096693","article-title":"Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994\u20132007","volume":"68","author":"Elliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib4","unstructured":"Office of national statistics. National population projections, \u3008http:\/\/www.ons.gov.uk\/ons\/rel\/npp\/national-population-projections\/2010-based-reference-volume\u2013series-pp2\/results.html#tab-Age-structure\/\u3009; 2012 [accessed May 2013]."},{"key":"10.1016\/j.semarthrit.2014.01.004_bib5","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib6","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","article-title":"Gout epidemiology: results from the UK general practice research database, 1990\u20131999","volume":"64","author":"Mikuls","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib8","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/ard.2007.070755","article-title":"Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations","volume":"66","author":"Roddy","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib9","first-page":"S349","article-title":"Gout treatment gaps and factors associated with incident patients having uric acid goal attainment: a retrospective cohort study in an integrated healthcare system","volume":"63","author":"Rashid","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/rheumatology\/41.5.503","article-title":"Improving the quality of care of musculoskeletal conditions in primary care","volume":"41","author":"Roberts","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib11","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthrit Care Res"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib12","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib13","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib14","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","article-title":"Gout: why is this curable disease so seldom cured?","volume":"71","author":"Doherty","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib15","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s100670050005","article-title":"How is gout managed in primary care? A review of current practice and proposed guidelines","volume":"19","author":"Pal","year":"2000","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib17","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib18","unstructured":"Datapharm. Electronic Medicines Compendium, \u3008http:\/\/www.medicines.org.uk\/emc\/medicine\/23722\/SPC\/\u3009; 2013 [accessed May 2013]."},{"key":"10.1016\/j.semarthrit.2014.01.004_bib19","first-page":"S1012","article-title":"Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed nomogram for safe starting dosing of allopurinol","volume":"63","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib20","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","article-title":"HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency","volume":"26","author":"Jung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2014.01.004_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017214000055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017214000055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:55:48Z","timestamp":1758732948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017214000055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0049017214000055"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2014.01.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Up-titration of allopurinol in patients with gout","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2014.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}